Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Lymphoma, B-Cell, Marginal Zone

Lymphoma, B-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

Lymphosarcoma

Marginal Zone Lymphoma

B-cell Lymphoma

Antineoplastic Agents

Antirheumatic Agents

All Drugs and Chemicals

Rituximab

Complement System Proteins

Antineoplastic Agents, Immunological

Immunologic Factors

10-20 mg (1-2 ml) rituximab once a week for 4 weeks; followed by 10-20 mg (1-2 ml) rituximab monthly per six months

intralesional rituximab

patients in PD or SD during or after administration of 6 doses monthly rituximab will be administered the same dose of intralesional rituximab supplemented by autologous serum

supplemental autologous serum

Andrés JM Ferreri, MD

Phase II, monocentric, open label study to assess safety and activity of intralesional Rituximab for the treatment of indolent CD20+ lymphoma of conjunctiva.

Preliminary data suggest intralesional rituximab is able to revert resistance to systemic rituximab in patients with CD20+ indolent lymphoma of the conjunctiva, and the addition of autologous serum seems to exhibit a synergistic effect on tumor regression. These two main aspects will be assessed in this trial.

Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma

Phase II Study on Activity and Tolerability of Intralesional Rituximab in Patients With Relapsed or Refractory CD20+ Indolent Lymphomas of Conjunctiva; Activity of Supplemental Autologous Serum in Patients Not Responsive to Rituximab Alone

assessment of safety of intralesional rituximab in terms of incidence of \>/= G4 adverse events during the experimental treatment

assessment of activity of intralesional rituximab in terms of overall partial and complete response and duration of response

Andres J. M. Ferreri

Behaviors and Mental Disorders

Aggression

Anti-Inflammatory Agents

Antiemetics

Gastrointestinal Agents

Gemcitabine

Antibodies

Antibodies, Monoclonal

Dexamethasone

Obinutuzumab

Cisplatin

Dexamethasone acetate

BB 1101

Immunoglobulins

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Antimetabolites

Obinutuzumab 1000mg by IV for 1.5-6.5 hours with Gemcitabine 1000mg/m\^2 by IV for 30 minutes with dexamethasone 40mg by mouth daily and Cisplatin 75mg/m\^2 by IV for 1 hour all for a duration of 3 cycles

This is a pilot study to determine the overall survival rate and toxicities of obinutuzumab given with GDP chemotherapy for relapsed or refractory CD20+ aggressive non-Hodgkin lymphoma. Patients who have CD20+ and progressed R-CHOP therapy will be enrolled into the study. About 30 patients are planned to be enrolled from Princess Margaret Cancer Centre.

If the enrollment is very slow then additional site may be included. Patients will receive Obinutuzumab +GDP for 3 cycles intravenously. CT scan will be used to evaluate the response rate after cycle 2 and PET-CT will be used after cycle 3. Responders (complete metabolic response, partial metabolic response) should proceed to autologous stem cell transplant (ASCT). Patients who have progressed after three cycles or less are to have their protocol treatment discontinued, with subsequent treatment at investigator discretion. Patients will be followed up to 24 months from transplant done or last chemo. Mandatory tissue submission and optional tissue and blood submission are required for the correlative component of this study.

Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Pilot Study of Obinutuzumab in Combination With GDP Chemotherapy for the Treatment of Relapsed or Refractory CD20+ Aggressive Non-Hodgkin Lymphoma

Hoffmann-La Roche

Ozmosis Research Inc.

University Health Network, Toronto

Lymphoma, Mantle-Cell

Mantle Cell Lymphoma

Patients who have received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin's lymphoma and Mantle cell lymphoma.

[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)

This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin's lymphoma and Mantle cell lymphoma. The objective of this study is to assess safety and efficacy of using Zevalin in clinical practice. This study is also all case investigation of which the enrollment period is five years, and all patients who received Zevalin will be recruited and followed 13 weeks after the administration.

Zevalin Post-marketing Surveillance in Japan

Drug Use Investigation of Zevalin

Bayer

Spectrum Pharmaceuticals, Inc

Symptoms and General Pathology

Recurrence

BTK inhibitor Orelabrutinib low dose or high dose; Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.

Orelabrutinib

Recombinant humanized monoclonal antibody MIL62 injection, 800mg or1000mg each time, Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.

Recombinant humanized monoclonal antibody MIL62 injection

Yuankai Shi, PhD

Dose escalation and expansion phase I/IIa clinical study of recombinant humanized type II CD20 monoclonal antibody MIL62 injection combined with a novel selective Bruton Tyrosine Kinase(BTK) inhibitor Orelabrutinib in the treatment of recurrent/refractory CD20+B cell lymphoma

A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

A Phase I/IIa Study on Dose-escalation and Extension of Recombinant Humanized Type II CD20 Monoclonal Antibody MIL62 Injection Combined With BTK Inhibitor Orelabrutinib in the Treatment of Recurrent/Refractory CD20+B-cell Lymphoma

pharmacokinetic parameter of MIL62 combined with Orelabrutinib in the treatment

Preliminary evaluation of MIL62 combined with Orelabrutinib in the treatment of relapsed/refractory CD20+B cell lymphoma with 3-year progression-free survival

Preliminary evaluation of MIL62 combined with Orelabrutinib in the treatment of recurrent/refractory CD20+B cell lymphoma with 3-year overall survival

Preliminary evaluation of remission duration of MIL62 combined with Orelabrutinib in the treatment of Recurrent/refractory Non Hodgkin Lymphoma

Preliminary evaluation of MIL62 combined with Orelabrutinib in the treatment of Recurrent/refractory Non Hodgkin Lymphoma with 3-year progression-free survival

Preliminary evaluation of MIL62 combined with Orelabrutinib in the treatment of Recurrent/refractory Non Hodgkin Lymphoma with 3-year overall survival

Beijing InnoCare Pharma Tech Co., Ltd.

ACTR087

rituximab

Jessica Sachs, MD

This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and efficacy of an autologous T-cell product expressing ACTR in combination with rituximab in subjects with refractory or relapsed CD20+ B-cell lymphoma.

Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma

Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-cell Receptors (CD16V-41BB-CD3ζ), in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Blood samples will be collected and analyzed for the presence of T-cells which express antibody coupled T-cell receptors, using flow cytometry and qPCR

Cogent Biosciences, Inc.

ACTR707

This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and anti-lymphoma activity of an autologous T cell product (ACTR707) in combination with rituximab in subjects with refractory or relapsed CD20+ B cell lymphoma.

Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma

Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma

Dose-limiting toxicities, MTD, incidence and severity of AEs and clinically significant abnormalities of laboratory values

Vinorelbine

Ifosfamide

Isophosphamide mustard

Tubulin Modulators

Antimitotic Agents

Antineoplastic Agents, Alkylating

Alkylating Agents

gemcitabine

vinorelbine

ifosfamide

Andrew Spencer, Assoc.Prof

This is a Phase II pilot study evaluating the safety of a risk-adjusted outpatient-based approach to lymphoma salvage therapy with VGF (vinorelbine, gemcitabine and pegfilgrastim) and/or F-GIV (gemcitabine, Ifosfamide, vinorelbine and pegfilgrastim) in combination with Rituximab (R-VGF/R-F-GIV).

Recent epidemiologic surveys have demonstrated a dramatic increase in the incidence of non-Hodgkin's lymphoma (NHL). NHL is now one of the most rapidly increasing malignancies in the industrial world.

The purpose of this project is to evaluate the efficacy and safety of an outpatient treatment for relapsed or treatment resistant (refractory) CD20+ lymphoma. Two combinations of chemotherapy drugs will be tested depending on the patients prior therapy and response - rituximab, vinorelbine and gemcitabine (R-VGF) OR rituximab, vinorelbine, gemcitabine and ifosfamide (R-FGIV).

Previous experience, including a recently completed study using combinations of vinorelbine, gemcitabine and ifosfamide has demonstrated that such an outpatient approach is safe and of similar efficacy to presently available alternative inpatient chemotherapy approaches. This study is expanding on the findings from the previous study by adding rituximab.

Rituximab is being increasingly and successfully used in the therapy of CD20+ NHL. It is a specific protein (antibody) that is directed against the surface protein (CD20 antigen) found on CD20+ lymphoma cells and can therefore lead to the destruction of these cells. Rituximab also has a highly favourable toxicity profile enabling outpatient treatment.

All of these factors provide a strong rationale for the combination of rituximab and the novel outpatient-based salvage approaches VGF and F-GIV that we have recently evaluated. This pilot study of 12 patients will test the feasibility of this combination approach in patients with relapsed/refractory CD20+ NHL.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma	NCT01514344	Ocular Adnexal ...	intralesional r... supplemental au...	18 Years -	IRCCS San Raffaele
Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	NCT02750670	Lymphoma, Non-H...	Obinutuzumab Gemcitabine Dexamethasone Cisplatin	16 Years - 70 Years	University Health Network, Toronto
Zevalin Post-marketing Surveillance in Japan	NCT01448928	Non-Hodgkin's L...	[90]Y-ibritumom...	-	Spectrum Pharmaceuticals, Inc
Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma	NCT01514344	Ocular Adnexal ...	intralesional r... supplemental au...	18 Years -	IRCCS San Raffaele
Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	NCT02750670	Lymphoma, Non-H...	Obinutuzumab Gemcitabine Dexamethasone Cisplatin	16 Years - 70 Years	University Health Network, Toronto
A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma	NCT04304040	B-cell Lymphoma... B-cell Lymphoma...	Orelabrutinib Recombinant hum...	18 Years -	Beijing InnoCare Pharma Tech Co., Ltd.
Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma	NCT02776813	Lymphoma	ACTR087 rituximab	18 Years - 75 Years	Cogent Biosciences, Inc.
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma	NCT03189836	Lymphoma	ACTR707 rituximab	18 Years - 80 Years	Cogent Biosciences, Inc.
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma	NCT03189836	Lymphoma	ACTR707 rituximab	18 Years - 80 Years	Cogent Biosciences, Inc.
Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma	NCT00280878	Non-Hodgkin's L...	gemcitabine vinorelbine ifosfamide rituximab	18 Years -	Bayside Health
A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma	NCT04304040	B-cell Lymphoma... B-cell Lymphoma...	Orelabrutinib Recombinant hum...	18 Years -	Beijing InnoCare Pharma Tech Co., Ltd.
Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma	NCT02776813	Lymphoma	ACTR087 rituximab	18 Years - 75 Years	Cogent Biosciences, Inc.

Spots Global Cancer Trial Database for cd20+

Every month we try and update this database with for cd20+ cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for cd20+

Every month we try and update this database with for cd20+ cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for cd20+ cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.